91.5%
disease-modifying therapyFabry disease68Ga-DOTATATEFabry cardiomyopathy
…R 57–70) years; 58% male; 50% classical phenotype. All received disease-modifying therapy. Focal 68Ga-DOTATATE uptake was present in all patients with he…
7,227articles mentioning treatments
16,644treatment mentions
4,719distinct treatments extracted
0%of mentions human-reviewed
All extracted treatments
Showing 2,821–2,880 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
alternative treatment options1ambulatory oxygen therapy1amyloid-clearing therapies1anaesthetics1analgesic strategies1androgen receptor inhibitors1aneurysm embolization1angioplasty and stenting1angiotensin II receptor blocker1anteroseptal line ablation1anthracycline-based therapy1anti- H.pylori treatment1anti-CD19 CAR-T therapy1anti-CD20 therapies1anti-CGRP therapies1anti-CTLA4 therapy1anti-HER2 therapies1anti-HER2 therapy1anti-IL5R therapy1anti-PD therapy1anti-PD-(L)1 therapy1anti-PD-1 therapies1anti-PD-1/PD-L1 therapies1anti-TB therapy1anti-TNF treatment1anti-TNF-α therapy1anti-TNFα treatment1anti-aTNF therapy1anti-amyloid immunotherapy1anti-amyloid monoclonal antibody therapies1anti-cancer interventions1anti-cancer treatments1anti-eosinophilic biologic therapy1anti-fibrinolytic treatment1anti-fungal induction therapy1anti-hypertensives1anti-infective therapy1anti-infective treatment1anti-inflammation1anti-inflammatory analgesia1anti-inflammatory diet1anti-inflammatory strategies1anti-inflammatory-based management1anti-interleukin-1 therapy1anti-metabolite therapy1anti-metastatic therapies1anti-osteoporotic medication1anti-programmed cell death ligand-1(PD-L1) therapy1anti-programmed cell death protein 1 (PD-1) therapy1anti-programmed cell death protein 1 ICB1anti-programmed cell death protein 1 immunotherapy1anti-programmed cell death protein-1 (PD-1) therapy1anti-programmed cell death-ligand 1 immunotherapy1anti-programmed death-ligand 1 therapy1anti-pyretics1anti-reflux therapy1anti-rejection medication1anti-rejection medications1anti-respiratory syncytial virus (RSV) antibody prophylaxis1anti-rheumatic therapy1
Articles mentioning treatments
7,227 articles · page 306 of 603revascularisationCoronary artery diseasemyocardial infarctionHoltackers et al
…iac events. Furthermore, regional functional recovery following revascularisation is shown to be highly dependent on infarct transmurality, and s…
disease-modifying treatmentmultiple sclerosisMSSpanish neuroimmunology centresAMH
…-up 6.5 years (0.01–29.4) and AMH 2.2 (0.01–17.4); 68% received disease-modifying treatment. AMH levels did not differ between patients and controls and we…
mechanical ventilationDiaphragm dysfunctionNCT07256821Wales Research Ethics Committee 4
…n Diaphragm dysfunction is associated with failure to wean from mechanical ventilation. Inspiratory muscle training (IMT) may help improve outcomes fo…
Auricular vagal neuromodulation therapyHospital Anxiety and Depression ScaleMedical University of ViennaPostural orthostatic tachycardia syndrome (POTS)POTS
…ed relief and do not sufficiently address non-cardiac symptoms. Auricular vagal neuromodulation therapy (AVNT) and slow-paced diaphragmatic breathing (SDB) have each d…
targeted therapiesSjDSjögren’s disease (SjD)
…l dysregulation. These insights have fuelled the development of targeted therapies designed to modulate specific immune pathways, aiming to interr…
electroconvulsive therapy
…team work together to manage the anxiety she experiences during electroconvulsive therapy…
second-line treatmentsICIparaneoplastic phenotypesnational reference center
… first-line treatments, and 33/163 patients (20%) also received second-line treatments. Early neurological recovery was observed in 82/164 patients (5…
treatment-as-usualalcohol-related diseasesDAIs
…ual cohorts: one receiving a DAI cohort and the other receiving treatment-as-usual (TAU cohort). We contrasted incidence rates for ten alcohol-rel…
maintenance therapyrituximabgranulomatosis with polyangiitisGPA
…or relapse, hospitalisation and damage accumulation risk during maintenance therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vascu…
Patient experiences of idiopathic pulmonary fibrosis (IPF) in China: a multicentre qualitative study
pharmacological therapiesIdiopathic pulmonary fibrosis (IPF)
…ng disease that profoundly impacts patients’ daily lives. While pharmacological therapies continue to advance, less is known about how patients experienc…
physiotherapySpinal muscular atrophy (SMA)
…n particular, gaps were noted in access to respiratory support, physiotherapy and nutritional management. These findings suggest that the app…